Inventiva announces a financing of approximately €35.7 million from new and existing investors, consisting of a €30.6 million reserved capital increase and a €5.1 million issuance of royalty certificates
Retrieved on:
목요일, 8월 31, 2023
Exercise, BofA Securities, Code, NASH, SEC Rule 144A, Equity carve-out, Public company, Transaction, Loi autorisant le divorce en France, Commercial code, SGLT2, Person, Qatar Investment Authority, Sale, Royalty payment, NPV, Patient, European, Fatty liver disease, ISIN, United Kingdom, European Investment Bank, Phase, EIB, III, Pharmaceutical industry, Security (finance), Life insurance, Cryptocurrency, Bank, Real estate, Music, EU, Euronext Paris
As a result, the Company will not have sufficient net working capital over the next twelve months after the Capital Increase and the issuance of the Royalty Certificates.
Key Points:
- As a result, the Company will not have sufficient net working capital over the next twelve months after the Capital Increase and the issuance of the Royalty Certificates.
- After the Capital Increase, Sofinnova Partner will hold 9.8% of the share capital of the Company, on a non-diluted basis.
- After the Capital Increase, Yiheng Capital will hold 7.4% of the share capital of the Company, on a non-diluted basis.
- The Royalty Certificates will not be listed on any stock exchange and will not be assigned an ISIN.